tbuckley/cabot-search huggingface dataset:
Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators
Authors: Fernando Ramos, Violeta Martinez-Robles, Joan Bargay, Guillermo Deben, Ana Garrido, Josefina Serrano, Olga Salamero, Juan Bergua, Enrique Colado, Regina Garcia, Carmen Pedro, Santiago Redondo, Mar Tormo, Santiago Bonanad, Maria Diez-Campelo, Manuel Perez-Encinas, Adolfo de la Fuente, Blanca Xicoy, Jose Falantes, Patricia Font, Tomas-Jose Gonzalez-Lopez, Guillermo Martin-Nuñez, Pau Montesinos, Fermin M. Sanchez-Guijo
Journal: Blood (2012)
Rituximab Plus Donor Lymphocyte Infusion (DLI) to Prevent or Treat Relapse for B Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)
Authors: Irene Cavattoni, Heike Schieder, Tatjana Zabelina, Ulrike Bacher, Francis Ayuk, Christine Wolschke, Axel R. Zander, Nikolaus Kroeger
Journal: Blood (2008)
Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.
Authors: Jennifer E Amengual, Sean Clark-Garvey, Matko Kalac, Luigi Scotto, Enrica Marchi, Celests Rojas, Ellen Neylon, Paul M Johannet, Salvia Jain, Jasmine M. Zain, Owen A. O'Connor
Journal: Blood (2012)
Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Is Active in B-Cell Lymphoma and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors
Authors: Sarah Frys, Matthew J. Barth, Cory Mavis, Juan Gu, John Gibbs, Myron S. Czuczman, Francisco Hernandez-Ilizaliturri
Journal: Blood (2012)
Management of Acute Myeloid Leukemia (AML) in First Relapse: Retrospective Analysis about 101 Adults Cases Receiving Homogeneous First-Line Therapy. Impact of Prognostic Factors and Treatment.
Authors: Cecile Fohrer, Brigitte Witz, Jean Luc Harousseau, Francis Witz, Shanti Ame, Frederic Maloisel, Karin Bilger, Raoul Herbrecht, Bruno Lioure
Journal: Blood (2004)
Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study
Authors: Christian Gisselbrecht, Olivier Fitoussi, Karim Belhadj, Nicolas Mounier, Pierre Feugier, Bertrand Coiffier, Christian Recher, Olivier Casasnovas, Catherine Sebban, Christophe Ferme, Josette Briere, Herve Tilly, Corinne Haioun
Journal: Blood (2008)
A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice
Authors: Hubert Plovier, Amandine Everard, Céline Druart, Clara Depommier, Matthias Van Hul, Lucie Geurts, Julien Chilloux, Noora Ottman, Thibaut Duparc, Laeticia Lichtenstein, Antonis Myridakis, Nathalie M Delzenne, Judith Klievink, Arnab Bhattacharjee, Kees C H van der Ark, Steven Aalvink, Laurent O Martinez, Marc-Emmanuel Dumas, Dominique Maiter, Audrey Loumaye, Michel P Hermans, Jean-Paul Thissen, Clara Belzer, Willem M de Vos, Patrice D Cani
Journal: Nature Medicine (2016)
Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease: Phase 2 and Long Term Efficacy, Safety and Immune Correlates
Authors: John Koreth, Haesook T. Kim, Kyle T. Jones, Carol G Reynolds, Marie J Chammas, Katherine Dusenbury, Jennifer Whangbo, Sarah Nikiforow, Edwin P. Alyea, Philippe Armand, Corey S Cutler, Vincent T Ho, Yi-Bin Chen, David Avigan, Joseph H Antin, Jerome Ritz, Robert J Soiffer
Journal: Blood (2014)
Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study.
Authors: Anas Younes, Amanda Wedgwood, Peter McLaughlin, Charalambos Andreadis, Sarit E. Assouline, Zuomei Li, Robert E. Martell, Marja Dubay, Tracy-Ann Patterson, Michelle R. Ward, Michael Crump
Journal: Blood (2007)
Overall Survival by Prognosis Score in High-Risk Myelodysplastic Syndromes (MDS) Patients Receiving Decitabine Treatment: Results From Clinical Experience
Authors: Marcelo Iastrebner, Jun Ho Jang, Kihyun Kim, Chul W. Jung, Elsa Nucifora, Federico Sackmann, Sergio Orlando, Graciela Klein, Juan Garcia, Carolina Belli, Luis Quiroga, Fernando Santini, Haydee i Bernard, Lino Salvatierra, Gustavo Taborda, Raquel Bengió
Journal: Blood (2011)
Autologous Stem Cell Transplantation (ASCT) as Consolidation Therapy for Patients with Low-Intermediate (LI) Risk Diffuse Large B-Cell Lymphoma (DLBCL) and Overexpression of Bcl2 Protein. Results of the First Interim Analysis of the GELA Trial LNH98-B2.
Authors: Pierre Morel, Nicolas Mounier, Josette Briere, Christophe Ferme, Bertrand Coiffier, Herve Tilly, Philippe Gaulard, Pierre Lederlin, Felix Reyes, Christian Gisselbrecht
Journal: Blood (2004)
Abstract 13881: Cardiac Progenitor Cell Infusion in Patients With Univentricular Heart Diseases in Heart Failure With Preserved Ejection Fraction
Authors: Daiki Ousaka, Takuya Goto, Shuta Ishigami, Shinichi Ohtsuki, Shingo Kasahara, Shunji Sano, Hidemasa Oh
Journal: Circulation (2015)

Backgrounds: The clinical outcomes of heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) after staged palliations in patients with univentricular heart disease remain unknown as is the question whether cardiosphere-derived cell (CDC) transfer may have impact on either type of cardiac dysfunction. Purpose: We sought to characterize the heart failure patients, include HFrEF and HFpEF, with single ventricular physiology and investigate the clinical responsiveness after CDC therapy. Methods: Forty-three patients, aged 2.2±1.4 years, undergoing staged shunt procedures were divided into two groups by cardiac function based on cMRI (HFrEF: EF&lt;40%, n=30; HFpEF: EF&gt;40%, n=13). Results: Compared with HFpEF patients, HFrEF patients showed increased cardiac volume (P=0.02) and mass index (P=0.04), those were associated with reduced global circumferential strain in HFrEF compared with HFpEF (P=0.0004). There was no difference in the incidence of late gadolinium enhancement detected by cMRI in both groups (20% in HFrEF and 15% in HFpEF). When patients underwent staged shunt procedures, HFpEF group had significant reduction in EF (P=0.03) and atrial strain (P=0.047), resulting in increase in Tei index 1 month after palliation (P=0.02). To investigate whether CDC infusion may affect the cardiac function in these two types of HF, patients were subjected to receive CDC injection 1 month post palliation. In contrast to HFpEF group, HFrEF patients demonstrated a marked improvement in EF (P=0.0006), right ventricular elastance (P=0.0005) 3 months after CDC infusion. Similarly, diastolic function improvements were found in CDC-treated HFrEF group but HFpEF patients as shown by increased atrial fractional area change (P=0.01) and reduced E-wave/e’sr (P=0.049). However, patients with HFpEF showed no improvement in diastolic function but significantly reduced dP/dt at 3 months (P=0.04). These beneficial effects by CDCs could not be seen in remaining 20 patients who were assigned to treat as palliation alone without CDC injection. Conclusions: HFpEF is common in univentricular heart diseases and that may have early perioperative right ventricular dysfunction and could be CDC therapy-resistant leading to latent heart failure.
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
Authors: E J Cheadle, G Lipowska-Bhalla, S J Dovedi, E Fagnano, C Klein, J Honeychurch, T M Illidge
Journal: Leukemia (2016)

Abstract Anti-CD20 monoclonal antibodies (mAb) such as rituximab have been proven to be highly effective at improving outcome in B-cell malignancies. However, many patients ultimately relapse and become refractory to treatment. The glycoengineered anti-CD20 mAb obinutuzumab was developed to induce enhanced antibody-dependent cellular cytotoxicity, antibody-dependent phagocytosis and direct cell death and was shown to lead to improved outcomes in a randomized study in B-CLL. We hypothesized that immune stimulation through Toll-like receptor 7 (TLR7) agonism in combination with obinutuzumab would further enhance lymphoma clearance and the generation of long-term antitumor immune responses. Here we demonstrate, in syngeneic human CD20 (hCD20)-expressing models of lymphoma, that systemic administration of a TLR7 agonist (R848) increases responses when administered in combination with obinutuzumab and protects against disease recurrence. Depletion studies demonstrate that primary antitumor activity is dependent on both NK cells and CD4 + T cells but not on CD8 + T cells. However, both CD4 + and CD8 + T cells appear necessary for the generation of protective immunological memory. Importantly, increased tumor-free survival post obinutuzumab and R848 combination therapy was seen in hCD20 transgenic mice, which express hCD20 on normal B cells. These findings provide a rationale for clinical testing of obinutuzumab in combination with systemically administered TLR7 agonists to further improve outcome.
A Selective Small Molecule Factor VIIa Inhibitor, CRA-027483, Suppresses Acute Inflammation in Mice.
Authors: Stacie A. Dalrymple, Florentino D. San Pablo, Juthamas Sukbuntherng, James W. Janc, Wendy B. Young, Dange Vijaykumar, Heleen Scheerens
Journal: Blood (2005)
Genomic Copy Number Alterations and Clustering Analysis Using Array CGH in Acute Myeloid Leukemia with Normal Karyotype.
Authors: Kyung Ran Jun, Eul-Ju Seo, Seo-Jin Park, Seongsoo Jang, Chan-Jeoung Park, Hyun-Sook Chi, Jung-Hee Lee, Je-Hwan Lee, Kyoo Hyung Lee
Journal: Blood (2009)
Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network
Authors: Meletios A. Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, Pierre Morel, Marie-Christine Kyrtsonis, Eirini Katodritou, Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Evangelos Terpos, Giampaolo Merlini, Efstathios Kastritis, Pieter Sonneveld
Journal: Blood (2010)
Loss of p53 Is Due to Rearrangements in a ~6,400 kb Region of Low Copy Repeats near the Centromere of Chromosome 17 in Chronic Lymphocytic Leukemia (B-CLL).
Authors: Gordon W. Dewald, Stephanie Fink, Stephanie Smoley, Kimberly Stockero, Sarah Paternoster, Schwager Susan, Erik C. Thorland, Daniel L. Van Dyke, Tait Shanafelt, Clive Zent, Timothy Call, Neil Kay
Journal: Blood (2005)
The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas
Authors: Chiara Tarantelli, Eugenio Gaudio, Ivo Kwee, Luciano Cascione, Elena Bernasconi, Petra Hillmann, Anastasios Stathis, Georg Stussi, Doriano Fabbro, Andreas Wicki, Emanuele Zucca, Vladimir Cmiljanovic, Francesco Bertoni
Journal: Blood (2015)
Towards Equity in Health: Researchers Take Stock
Authors: Annette Rid, Michael A. Johansson, Gabriel Leung, Hannah Valantine, Esteban G. Burchard, Sam S. Oh, Cathy Zimmerman
Journal: PLoS Medicine (2016)

For the 2016 end-of-the-year editorial, the PLOS Medicine editors asked 7 global health leaders to discuss developments relevant to the equitable provision of medical care to all populations. The result is a collection of expert views on ethical trial design, research during outbreaks, high-burden infectious diseases, diversity in research and protection of migrants.
Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy for Relapsed Multiple Myeloma.
Authors: Rebecca L. Olin, David L. Porter, Selina M. Luger, Stephen J. Schuster, Donald Tsai, Sunita Nasta, Alexander Perl, Alison W. Loren, Steven Goldstein, Eli Glatstein, Donald L. Siegel, Dan T. Vogl, Patricia Mangan, Kathleen Cunningham, Edward A. Stadtmauer
Journal: Blood (2005)
Clinical Relevance of Multidrug Resistance Proteins Expression in Patients with De Novo Acute Myeloid Leukaemia.
Authors: Maria Podolak-Dawidziak, Danuta Dus, Marek Kielbinski, Maria Paprocka, Olga Haus, Malgorzata Kuliszkiewicz-Janus, Kazimierz Kuliczkowski
Journal: Blood (2006)
Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases
Authors: Guillaume Passot, Olivier Soubrane, Felice Giuliante, Giuseppe Zimmitti, Diane Goéré, Suguru Yamashita, Jean-Nicolas Vauthey
Journal: Liver Cancer (2016)

The liver is the most common site of metastases for colorectal cancer, and combined resection with systemic chemotherapy is the most effective strategy for survival. The aim of this article is to provide a comprehensive summary on four hot topics related to chemotherapy and surgery for colorectal liver metastases (CLM), namely: (1) chemotherapy-related liver injuries: prediction and impact, (2) surgery for initially unresectable CLM, (3) the emerging role of RAS mutations, and (4) the role of hepatic arterial infusion of chemotherapy (HAIC).(1) The use of chemotherapy before liver resection for CLM leads to drug-specific hepatic toxicity, which negatively impacts posthepatectomy outcomes. (2) Curative liver resection of initially unresectable CLM following conversion chemotherapy should be attempted whenever possible, provided that a safe future liver remnant volume is achieved. (3) For CLM, RAS mutation status is needed to guide the use of targeted chemotherapy with anti-epithelial growth factor receptor (EGFR) agents, and is a major prognostic factor that may contribute to optimize surgical strategy. (4) HAIC agents increase the rate of objective response and the rate of complete pathological response.
Significance of the IL-3 Receptor Beta Chain (IL-3Rbc) for FLT3-ITD Dependent Oncogeneic Signaling in AML
Authors: Christoph Rummelt, Sivahari Prasad Gorantla, Philip Keye, Kathrin Klaesener, Venkatesh Rao, Christian Peschel, Michael Reth, Justus Duyster, Nikolas von Bubnoff
Journal: Blood (2015)
Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood
Authors: Akiko Eguchi, Raul G. Lazaro, Jiaohong Wang, Jihoon Kim, Davide Povero, Brandon Willliams, Samuel B. Ho, Peter Stärkel, Bernd Schnabl, Lucila Ohno‐Machado, Hidekazu Tsukamoto, Ariel E. Feldstein
Journal: Hepatology (2016)

Extracellular vesicles (EVs) released during cell stress, or demise, can contain a barcode of the cell origin, including specific microRNAs (miRNAs). Here, we tested the hypothesis that during early alcoholic steatohepatitis (ASH) development, hepatocytes (HCs) release EVs with an miRNA signature that can be measured in circulation. A time‐course experiment showed that after 2 weeks of intragastric infusion, a time point that results in isolated steatosis, there was no increase of blood EVs. After 4 weeks of infusion, mice developed features of early ASH accompanied by a marked increase in the level of EVs in blood ( P &lt; 0.05), as well as in culture media of isolated HCs ( P &lt; 0.001) and hepatic macrophages ( P &lt; 0.001), with HCs being the predominant source of EVs. The transcriptome analysis of HC‐EVs from ASH mice detected differentially expressed miRNAs, including nine significantly up‐regulated and four significantly down‐regulated miRNAs. Target prediction and pathway analyses of the up‐regulated miRNAs identified 121 potential target genes involved in inflammatory and cancer pathways, such as nuclear factor kappa B, EGF, Wnt, and B‐cell lymphoma 2. Three miRNAs, let7f, miR‐29a, and miR‐340, were increased in blood EVs from ASH mice ( P &lt; 0.05), but not in blood EVs from three other models of chronic liver injury, including bile duct ligation, nonalcoholic steatohepatitis, and obese mice, as well as EVs released from hepatocytes exposed to ethanol. Blood EV level ( P &lt; 0.01) and three miRNAs ( P &lt; 0.05) were significantly increased in patients with ambulatory mild ALD as compared to nonalcoholics. Conclusion : Damaged hepatocytes from ASH mice are a key EV source with a specific miRNA cargo, which are specific for ASH‐related liver injury. These findings uncover EVs as a potentially novel diagnostic for ASH. (H epatology 2017;65:475‐490).
A Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Hodgkin Lymphoma
Authors: Miguel-Angel Perales, Christina Cho, Anne Eaton, Alison J Moskowitz, Victoria Nguyen, Anne Marie R. Gonzales-Dadiz, Sean Devlin, Sergio A. Giralt, Ann A. Jakubowski, Matthew J. Matasar, Ariela Noy, Carol S. Portlock, David J. Straus, James W. Young, Juliet N. Barker, Craig H. Moskowitz
Journal: Blood (2015)
NICE advises routine high sensitivity troponin tests to rule out MI
Authors: Jacqui Wise
Journal: BMJ (2016)

All patients with acute chest pain who are assessed as having medium or high risk of a myocardial infarction (MI) should be given high sensitivity troponin blood tests, guidance from National Institute for Health and Care Excellence (NICE) advises. This will allow doctors to make a diagnosis much more quickly and should allow many patients to be discharged earlier.1

Cardiac troponins are proteins released into the bloodstream when the heart muscle is damaged—for example, …
AT-101, a Pan-Inhibitor of Bcl-2 Family Anti-Apoptotic Proteins Antagonizes the Protective Effect Conferred by Nurselike Cells on Primary Chronic Lymphocytic Leukemia (CLL) Cells.
Authors: Danelle F. James, Rebecca M. Mervis, Ruzbeh Mosadeghi, Thomas J. Kipps
Journal: Blood (2006)
Bill to boost medical research funding and speed drug approval passes US house
Authors: Michael McCarthy
Journal: BMJ (2016)

After two years of negotiations, the controversial 21st Century Cures Act was passed by the US House of Representatives on Wednesday 30 November by a vote of 392 to 26.1 The bill boosts funding for medical research and mental health and substance abuse care—but also contains provisions to speed up drug and medical device approval that consumer groups say will lower safety standards and put patients at risk.

Representative Fred Upton, a Republican from Michigan, and Representative Diana DeGette, a Democrat …
SHP-1 (PTPN6) Gene Supression by FLT3/ITD Defines an Aggressive Subgroup of Myeloid Malignancies.
Authors: Armando V. Mena-Duran, Juan C. Pajuelo, Jose Cervera-Zamora, Zaida Garcia-Casado, Ana Valencia, Eva Barragan, Luis Benlloch, Tomas Mustelin, Guillermo Sanz, Miguel A. Sanz
Journal: Blood (2006)
Signaling and Immunophenotypic Diversity in Pediatric Acute Myeloid Leukemia As Defined by 31-Parameter Single-Cell Mass Cytometry
Authors: Erin F. Simonds, Sean C Bendall, Kara L. Davis, Harris G Fienberg, Rachel L Finck, El-ad D. Amir, Ina Radtke, James R. Downing, Dana Pe'er, Garry P. Nolan
Journal: Blood (2011)
Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed By Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-Trial (T-PLL2) Conducted By the German CLL Study Group (GCLLSG)
Authors: Natali Pflug, Georg Hopfinger, Paula Cramer, Alexandra Schrader, Nicole Weit, Rita Meister, Miriam Thiel, Tanja Annolleck, Anne Westermann, Till M Seiler, Thorsten Zenz, Jan Duerig, Jasmin Bahlo, Karl-Anton Kreuzer, Stephan Stilgenbauer, Anna-Maria Fink, Barbara Eichhorst, Michael Hallek, Marco Herling
Journal: Blood (2014)
Phase 1/2 Clinical Trial of HQK-1001, An Oral Fetal Hemoglobin Stimulant, In Sickle Cell Anemia
Authors: Abdullah Kutlar, Kenneth I. Ataga, Marvin Reid, Loray A Blair-Britt, Elliott Vichinsky, Lynne Neumayr, Richard J. Labotka, Jonathan Glass, Andrea Small-WIlliams, Jeffrey Keefer, Ling Shen, Michael S Boosalis, Audrey Thomson, Patrick Bobbitt, Wayne Wallis, Elsa Johnson, Ronald J Berenson, Susan P Perrine
Journal: Blood (2010)
Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients (Pts) with Epstein Barr Virus (EBV)+ and/or CD30+ Lymphoma: Phase I Results of an Ongoing Phase I-II Study
Authors: Mitul Gandhi, Shuo Ma, Sonali M. Smith, Chadi Nabhan, Andrew M. Evens, Jane N. Winter, Leo I. Gordon, Adam M. Petrich
Journal: Blood (2014)
Multiple Myeloma Patients Treated with Allogeneic Stem Cell Transplantation Show an Increased Frequency of Bone Marrow-Residing CD4+Foxp3+ T Regulatory Cells.
Authors: Djordje Atanackovic, Yanran Cao, Christiane Faltz, Katrin Bartels, Christine Wolschke, Tim H. Brummendorf, Axel R. Zander, Carsten Bokemeyer, Nicolaus Kroeger
Journal: Blood (2006)
HIF-2alpha Associated Familial Erythrocytosis Supports the PHD2-HIF- 2alpha-VHL Axis as the Major Regulator of Erythropoietin Production
Authors: Melanie Percy, Paul W Furlow, Philip A Beer, Gavin Campbell, Adriaan W. Dekker, Anthony R. Green, Xiping Li, Scott Sutherland, David Oscier, M. Glenn Rainey, Enid Rivera, Richard van Wijk, Marion Wood, Terence R.J. Lappin, Mary Frances McMullin, Frank S Lee
Journal: Blood (2008)
A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies
Authors: Carmelo Carlo-Stella, Richard Delarue, Prajak J Barde, Lydia Scarfo, Thamila Saheb, Uday Kumar, Srikant Viswanadha, Sara Gandolfi, Valeria Pittari, Armando Santoro, Silvia Laura Locatelli, Swaroop Vakkalanka, Paolo Ghia, Andres J.M. Ferreri
Journal: Blood (2015)
Randomized Trial of Pleural Fluid Drainage Frequency in Patients with Malignant Pleural Effusions. The ASAP Trial
Authors: Momen M. Wahidi, Chakravarthy Reddy, Lonny Yarmus, David Feller-Kopman, Ali Musani, R. Wesley Shepherd, Hans Lee, Rabih Bechara, Carla Lamb, Scott Shofer, Kamran Mahmood, Gaetane Michaud, Jonathan Puchalski, Samaan Rafeq, Stephen M. Cattaneo, John Mullon, Steven Leh, Martin Mayse, Samantha M. Thomas, Bercedis Peterson, Richard W. Light
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Patients with malignant pleural effusions have significant dyspnea and shortened life expectancy. Indwelling pleural catheters allow patients to drain pleural fluid at home and can lead to autopleurodesis. The optimal drainage frequency to achieve autopleurodesis and freedom from catheter has not been determined.To determine whether an aggressive daily drainage strategy is superior to the current standard every other day drainage of pleural fluid in achieving autopleurodesis.Patients were randomized to either an aggressive drainage (daily drainage; n = 73) or standard drainage (every other day drainage; n = 76) of pleural fluid via a tunneled pleural catheter.The primary outcome was the incidence of autopleurodesis following the placement of the indwelling pleural catheters. The rate of autopleurodesis, defined as complete or partial response based on symptomatic and radiographic changes, was greater in the aggressive drainage arm than the standard drainage arm (47% vs. 24%, respectively; P = 0.003). Median time to autopleurodesis was shorter in the aggressive arm (54 d; 95% confidence interval, 34-83) as compared with the standard arm (90 d; 95% confidence interval, 70 to nonestimable). Rate of adverse events, quality of life, and patient satisfaction were not significantly different between the two arms.Among patients with malignant pleural effusion, daily drainage of pleural fluid via an indwelling pleural catheter led to a higher rate of autopleurodesis and faster time to liberty from catheter. Clinical trial registered with www.clinicaltrials.gov (NCT 00978939).
Characterization of Subclonal Changes Along Progression in Multiple Myeloma.
Authors: Joaquin Martinez Lopez, Margarita Sanchez Beato, Martinez Nerea, Ignacio Varela, Sophia Derdak, Inmaculada Rapado, Sergi Beltran, Sara Martinez Sayalero, Laura Cereceda, Monica Bayes, Marta Gut, Ivo G. Gut, Miguel Angel Piris
Journal: Blood (2012)
Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC)
Authors: Rami S. Komrokji, Amy E. DeZern, Katrina Zell, Najla H. Al Ali, Eric Padron, Christopher Estling, Cassie Zimmerman, Wesley Hand, Francis Brown, Nicole Rizzo, John Barnard, Gail J Roboz, Hetty E. Carraway, Jaroslaw P. Maciejewski, Alan F. List, Guillermo Garcia-Manero, David P. Steensma, Mikkael A. Sekeres
Journal: Blood (2015)